BrilliantStrings Therapeutics

Home.


BrilliantStrings is a mechanotherapeutics company with a focus on Complete Human Collagen(CHC™)

About Us

BrilliantStrings Therapeutics has transformed decades of paradigm-shifting academic research in extracellular matrix mechanochemistry and deep expertise in controlling collagen assembly into a unique, healing biomaterial. Our Complete Human Collagen (CHC™) mechano-therapeutic, is capable of rapidly repairing injured or degenerated connective tissue and constitutes “a first-in-class” achievement. The CHC™ delivery platform addresses a very large unmet need for a wide range of Ortho-Musculoskeletal conditions. Our first target market is the Rotator Cuff.

A next generation approach to healing

In comparison to currently available ‘first generation’ therapeutics that are weakly effective, BrilliantStrings has a ‘next generation’ solution: a complete human collagen biomaterial AND platform that makes a quantum leap forward in the effort to produce complete and rapid healing. The company has systematically developed unique know-how to manufacture human collagen at commercial scale as well as the approach to precisely target and deliver a highly-efficient injectable collagen dose directly to the injury site. Together, these technical advances promise to usher in a new paradigm for orthopedic musculoskeletal injury treatment and wound healing.

Stable Complete Collagen Packaged for Delivery

Proprietary liquid-crystal packaging protects complete collagen and controllably delivers it to injury. Patent Filed.

Company.


Company Background

BrilliantStrings Therapeutics (BSTHX) is a healing biomaterials platform company that provides rapid repair and improved recovery of injured or age-degenerated human connective tissues found throughout the body (as depicted below). Our unique approach to healing transcends current ‘first generation’ collagen therapies and ushers in a new paradigm of active healing in orthopedics. We are the first company to provide a complete human collagen-based healing solution not only for clinically significant tissue tears that require surgical intervention, but also for the millions of people who do not yet qualify for surgery and suffer untreated and in chronic pain.

Injectable Therapeutic

To address the majority of patients pursing orthopedic treatment in the rotator cuff space but presenting an injury that does not require surgical repair, we will offer injections of complete human collagen comprising the same materials as the patch. We take our inner layer patch material, particulate it into micro-particles of dense 400 mg/ml collagen, and suspend the particles in solution to achieve a controlled release, 10 – 200 mg/ml injectable. Our collagen maintains the less stable configuration for dissociation into the wound site, and this is further enhanced by the increased available surface area achieved through the particulation process. Live ultrasound imaging permits the identification and precise locating of the injury. This allows clinicians to deliver the collagen solution within immediate proximity of the tissue damage for rapid repair.

Science.


Our science tells us that delivering Complete Collagen will improve outcomes!

Scientific Breakthrough

injury targeting

Collagen molecules “home” to injury and with the proper application of force, will promote the healing process.

Team.


BrilliantStrings Team

Jeffrey Ruberti

Jeff Ruberti, Ph.D.

CEO

Professor of Bioengineering
Northeastern University
Fellow AIMBE 2022

Jeffrey Ruberti

Martha Shadan, MBA

Board Chairwoman

Former CEO Rotation Medical
Former CEO Miach Orthopaedics
AdvaMed Board Member

Luke Oh

Luke Oh, M.D.

Consultant Surgeon

Medical Director of Orthopaedic Sports Medicine, Rothman Orthopaedics FL & AdventHealth
Head Team Surgeon, Orlando Magic (NBA)

JJ Paten

JJ Paten, Ph.D.

Chief Scientist

Lecturing Faculty
Mechanical Engineering
Harvard University

Scott Weiss

Scott Weiss, MBA

Chief Operations

Business Founder
Jackson Oakmont LLC
Author

News.


BST is Named as an Awardee in Johnson & Johnson Innovation and The Johnson & Johnson Family of Companies in Japan Inaugural Smart Healthy Aging QuickFire Challenge

FOR IMMEDIATE RELEASE

Lincoln, MA - BrilliantStrings Therapeutics is developing transformative, direct protein therapies to accelerate the healing of soft connective tissues, is pleased to announce that we are one of 4 companies to be selected as an awardee in the Johnson & Johnson Innovation and The Johnson & Johnson Family of Companies in Japan Inaugural Smart Healthy Aging QuickFire Challenge. "This inaugural QuickFire challenge was designed to identify companies and technologies to aid in Japan's aging population. We are thrilled that the team at Johnson & Johnson Innovation and The Johnson & Johnson Family of Companies in Japan recognized the healing properties of CHC™ and the promise it brings to the elderly patient population" said Dr. Jeffrey Ruberti, CEO of BrilliantStrings. "Our injectable CHC™ product is focused on healing tissue damage too small for surgical repair."

Related Links:
Johnson & Johnson Innovation
Twitter

Careers.


Company Overview:

BrilliantStrings Therapeutics is a pioneering biotechnology startup headquartered at JLabs @LabCentral in Cambridge, MA. We specialize in advancing orthopedic wound healing through direct-protein therapy. Our mission is to develop a comprehensive wound care platform that hyper-accelerates the healing of collagen-based tissues. As an early-stage startup, we are actively seeking visionary individuals to join us as the leaders of our scientific team. All research endeavors will adhere to rigorous FDA requirements, emphasizing the need for meticulous documentation to ensure regulatory compliance.

Position Overview:

As Senior Scientist, you will play a pivotal role in advancing our therapeutic development program. The ideal candidate will be a key contributor to our orthopedic wound healing technology by utilizing their expertise in cell culture, adherent bioreactors, and engineering of mammalian and human cells (e.g., fibroblasts). Bio-orthogonal labeling of the produced proteins will be an important aspect of the work.

Key Responsibilities:

  1. Engineer mammalian and human cells to optimize large protein upregulation.
  2. Ensure the stability of cell lines during the upregulation process, implementing measures to maintain the integrity and functionality of engineered cells.
  3. Develop and implement methodologies for quantifying production rates of therapeutic proteins, providing essential insights into the efficiency and productivity of cell culture processes.
  4. Employ analytical tools and techniques to assess and enhance overall production performance within the therapeutic development program.
  5. Lead the strategic scaling of cell culture processes, identifying opportunities for increased efficiency and scalability.
  6. Innovate and refine protocols for bio-orthogonal labeling of synthesized proteins.
  7. Collaborate with cross-functional teams to implement scalable solutions, ensuring seamless integration into the broader orthopedic wound healing platform.

Qualifications:

  1. Ph.D. in a relevant scientific discipline (Cell Biology, Molecular Biology, Bioengineering, Biomedical Engineering, or related field).
  2. Proven experience and proficiency in cell engineering to promote protein production (e.g. CRISPRa), establishing cell lines, assessing and optimizing protein expression.
  3. Demonstrated familiarity with different cell culture bioreactors and ability to scale cell culture processes for increased efficiency and productivity.

To Apply:

Please contact BrilliantStrings at Apply

Company Overview:

BrilliantStrings Therapeutics is a pioneering biotechnology startup headquartered at JLabs @LabCentral in Cambridge, MA. We specialize in advancing orthopedic wound healing through direct-protein therapy. Our mission is to develop a comprehensive wound care platform that hyper-accelerates the healing of collagen-based tissues. As an early-stage startup, we are actively seeking visionary individuals to join us as the leaders of our scientific team. All research endeavors will adhere to rigorous FDA requirements, emphasizing the need for meticulous documentation to ensure regulatory compliance.

Position Overview:

As Senior Scientist, you will play a pivotal role in advancing our therapeutic development program. Key responsibilities will involve formulating our therapeutic for optimal delivery and integration into damaged tissues at various stages of healing. Formulations will be tested both in vitro and in animal studies to assess the benefits of different compositions. Additionally, your role will extend to integrating sterilization procedures seamlessly into the product development.

Key Responsibilities:

  1. Lead the development and optimization of therapeutic formulations to enhance tissue integration.
  2. Plan and execute comprehensive in vitro experiments to assess the efficacy and safety of formulated therapeutics.
  3. Conduct and oversee animal studies to evaluate the benefits of different therapeutic compositions, providing valuable insights for clinical applications.
  4. Integrate sterilization procedures into the product development process, ensuring safety and compliance.
  5. Evaluate and select appropriate sterilization methods, considering their impact on therapeutic integrity, and collaborate with quality assurance teams on validation processes.

Qualifications:

  1. Ph.D. in a relevant scientific discipline (Biomaterials, Biochemistry, Bioengineering, Biomedical Engineering, or related field).
  2. Relevant publications in biomaterials, drug delivery, or a closely related discipline.
  3. Hands-on experience in formulating and developing biomaterial or therapeutic products, preferably in biotechnology or pharmaceutical settings.
  4. Proven success in designing and executing in vitro and in vivo studies.
  5. Knowledge of international regulatory requirements for therapeutic development is a plus.

To Apply:

Please contact BrilliantStrings at Apply

Company Overview:

BrilliantStrings Therapeutics is a pioneering biotechnology startup headquartered at JLabs @LabCentral in Cambridge, MA. We specialize in advancing orthopedic wound healing through direct-protein therapy. Our mission is to develop a comprehensive wound care platform that hyper-accelerates the healing of collagen-based tissues. As an early-stage startup, we are actively seeking visionary individuals to join us as the leaders of our scientific team. All research endeavors will adhere to rigorous FDA requirements, emphasizing the need for meticulous documentation to ensure regulatory compliance.

Position Overview:

As Senior Scientist, you will play a pivotal role in advancing our therapeutic development program. Key responsibilities will involve formulating our therapeutic for optimal delivery and integration into damaged tissues at various stages of healing. Formulations will be tested both in vitro and in animal studies to assess the benefits of different compositions. Additionally, your role will extend to integrating sterilization procedures seamlessly into the product development.

Key Responsibilities:

  1. Establish and optimize protocols for efficient protein extraction from both cell culture and tissue.
  2. Continuously refine and enhance extraction methodologies to ensure maximum yield and purity.
  3. Design and implement purification processes to isolate individual proteins from complex biological samples. Evaluate and implement cutting-edge techniques to enhance product quality.
  4. Conduct rigorous characterization and qualification assessments of extracted proteins.
  5. Implement quality control measures to ensure the consistency and purity of the final product.
  6. Lead exploratory scientific studies using extracted biologics to advance therapeutic development.
  7. Contribute to the design and execution of experiments aimed at expanding the understanding of protein-based therapeutic applications.
  8. Collaborate with interdisciplinary teams to integrate protein extraction findings into the overall therapeutic development strategy.

Qualifications:

  1. Ph.D. in a relevant scientific discipline (Biochemistry, Molecular Biology, Analytical Chemistry, Cell Biology, or related field).
  2. Hands-on experience in ECM protein extraction and purification. Proven track record of successful characterization of proteins. Familiarity with the hydroxyproline assay is a plus.
  3. Experience with analytical techniques such as mass spectrometry, HPLC, SDS PAGE, Western Blot, and ELISA.

To Apply:

Please contact BrilliantStrings at Apply


Contact.


Learn more about our technology.

Copyright© BrilliantStrings Therapeutics 2022